Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
C5a Aphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Overview
C5a Aphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
C5a Aphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
C5a Aphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Companies Involved in Therapeutics Development
Alsonex Pty Ltd
ChemoCentryx Inc
Dompe Farmaceutici SpA
Inte Pharma SA
MorphoSys AG
Prommune Inc
Teva Pharmaceutical Industries Ltd
C5a Aphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Drug Profiles
ALS-205 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
avacopan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
avdoralimab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DF-2593A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Antagonize C5aR for Periodontitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EP-67 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MOR-210 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PMX-205 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Antagonize CD88 for Musculoskeletal, Gastrointestil, Autoimmune and Central Nervous System Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C5a Aphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Dormant Products
C5a Aphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Discontinued Products
C5a Aphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Product Development Milestones
Featured News &Press Releases
Nov 11, 2020: I-Mab announces preclinical data on differentiated Anti-C5aR Antibody TJ210/MOR210 at SITC 2020
Nov 06, 2020: ChemoCentryx announces plery session at ACR Convergence 2020 to highlight findings of ADVOCATE phase III trial in ANCA-associated vasculitis
Nov 03, 2020: VFMCRP and ChemoCentryx announce European Medicines Agency has accepted to review the Marketing Authorization Application for avacopan
Oct 28, 2020: ChemoCentryx announces positive topline results of phase II AURORA clinical trial of Avacopan in the treatment of hidradenitis suppurativa (HS)
Oct 27, 2020: I-Mab to present preclinical data of TJ210 at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Sep 17, 2020: MorphoSys and I-Mab announce FDA clearance of IND application for MOR210/TJ210 in patients with advanced cancer
Sep 17, 2020: ChemoCentryx announces FDA acceptance of the Avacopan new drug application (NDA) for the treatment of ANCA-associated vasculitis
Jul 29, 2020: Inte Pharma announces publication of EXPLORE COVID-19 translatiol study findings in ture
Jul 09, 2020: ChemoCentryx submits New Drug Application to the U.S. FDA for avacopan in ANCA-associated vasculitis
Jun 03, 2020: ChemoCentryx phase III ADVOCATE trial of Avacopan in ANCA-Associated Vasculitis highlighted in oral plery presentations at EULAR and ERA-EDTA Congresses
Apr 28, 2020: First patient dosed in Avdoralimab phase II clinical trial in covid-19 patients with severe pneumonia
Nov 27, 2019: VFMCRP and ChemoCentryx report positive data for avacopan
Nov 25, 2019: ChemoCentryx and VFMCRP announce positive topline data from pivotal phase III ADVOCATE trial demonstrating avacopan’s superiority over standard of care in ANCA-Associated Vasculitis
Nov 06, 2019: Inte Pharma announces preclinical data presentations on IPH-5401 at SITC 2019
Nov 06, 2019: Inte Pharma announces preclinical data on its Oncology drug candidate IPH-5401 at SITC 2019
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Top 10 Indications, H2 2020
Number of Products by Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020


List of Tables


Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Indications, H2 2020
Number of Products under Development by Indications, H2 2020 (Contd..1), H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Number of Products under Investigation by Universities/Institutes, H2 2020
Products under Investigation by Universities/Institutes, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Pipeline by Alsonex Pty Ltd, H2 2020
Pipeline by ChemoCentryx Inc, H2 2020
Pipeline by Dompe Farmaceutici SpA, H2 2020
Pipeline by Innate Pharma SA, H2 2020
Pipeline by MorphoSys AG, H2 2020
Pipeline by Prommune Inc, H2 2020
Pipeline by Teva Pharmaceutical Industries Ltd, H2 2020
Dormant Products, H2 2020
Dormant Products, H2 2020 (Contd..1), H2 2020
Discontinued Products, H2 2020